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Abstract Pilocytic astrocytoma (PA) is the most com-
mon tumor of the pediatric central nervous system (CNS).
A body of research over recent years has demonstrated a
key role for mitogen-activated protein kinase (MAPK)
pathway signaling in the development and behavior of PAs.
Several mechanisms lead to activation of this pathway in
PA, mostly in a mutually exclusive manner, with consti-
tutive BRAF kinase activation subsequent to gene fusion
being the most frequent. The high specificity of this fusion
to PA when compared with other CNS tumors has diag-
nostic utility. In addition, the frequency of alteration of this
key pathway provides an opportunity for molecularly tar-
geted therapy in this tumor. Here, we review the current
knowledge on mechanisms of MAPK activation in PA and
some of the downstream consequences of this activation,
which are now starting to be elucidated both in vitro and in
vivo, as well as clinical considerations and possible future
directions.
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NF1 Neurofibromatosis Type 1
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OIS Oncogene-induced senescence






Brain tumors are the most common solid tumors of
childhood, representing approximately a quarter of all
pediatric neoplasia [1]. The most common histological
entity in this setting is pilocytic astrocytoma (PA), which
accounts for approximately 20% of brain tumors under the
age of 20 [2, 3]. The most frequent sites of PA occurrence
are the cerebellum and the hypothalamic/chiasmatic
region, but they can also arise throughout the intracranial
space, including the cerebral hemispheres and brain stem,
and also rarely the spinal cord [4]. They are typically seen
to be slow-growing, well-circumscribed tumors, which do
not invade surrounding tissues and virtually never pro-
gress to higher malignancy grades. Dissemination into the
spinal canal at diagnosis has been reported, but this is a
rare event occurring in only 2–3% of cases [5]. As such,
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they are classified as malignancy grade I by the World
Health Organisation, and prognosis in terms of overall
survival is very good: [90% of patients survive beyond
10 years, and the majority of these long-term survivors are
cured of their tumor [6, 7]. Despite this, local recurrence
of tumor growth, even after complete resection (as
assessed by surgical report and/or postoperative MRI),
occurs in about 10–20% of cases. Rates of progression in
cases where the primary lesion was not amenable to gross
total resection can be as high as 50–80%. Both the pri-
mary tumor and subsequent recurrence, as well as the
treatments thereof, can also cause significant physical
morbidity or psychosocial dysfunction [8]. The introduc-
tion of novel, targeted therapeutics could therefore be of
significant benefit in treating this tumor of the childhood
brain, especially since, in contrast to most other tumor
entities, it can become in effect a chronic disease which
might require long-term and/or repeated cycles of adju-
vant therapy.
Histologically, diagnosis of PA can often be challeng-
ing. Classic presentation includes a biphasic architecture,
with areas of densely packed, fibrillary tissue interspersed
with looser microcystic compartments. Tumor cells usually
display an elongated morphology with hair-like (piloid)
tendrils that give the tumor its name. Rosenthal fibres
(strongly eosinophilic structures of unknown composition)
and granular bodies are also frequently observed, but are
neither necessary nor sufficient for diagnosis. It is now well
recognized that PAs can show widely varying morphology,
with regions reminiscent of higher-grade astrocytoma,
oligodendroglioma and ependymoma. Areas of necrosis
and marked vascular proliferation, more often seen in
highly malignant glioblastomas, are also occasionally
observed [6], highlighting the clinical importance of sen-
sitive and specific diagnostic markers for PA.
Until recently, very little was known about the genetic
alterations underlying this disease. Most early copy-num-
ber studies showed either balanced karyotypes or whole-
chromosomal changes, with analyses of candidate genes
altered in higher-grade astrocytoma (such as PTEN or
TP53) revealing very few mutations [9–12]. However, the
past few years have brought a substantial increase in our
understanding of some of the key genetic alterations
behind the development of PA, with several mechanisms
converging on abnormal activation of the mitogen-acti-
vated protein kinase/extracellular signal-regulated kinase
(MAPK/ERK) signaling pathway. Expanding on previous
reviews in this area [13, 14], the present review focuses on
these recent advances in our knowledge of PA tumori-
genesis, and also looks ahead to how these insights might
be expanded on in the future, both in terms of basic
biology and with regards to transferring these data to the
bedside.
MAPK signaling in normal brain and high-grade
astrocytomas
Under non-pathological conditions, MAPK/ERK signaling
components are expressed in most regions of the brain, and
show a largely overlapping expression pattern (with the
exception of MEK2, which is almost completely absent)
[15]. Functionally, this signaling pathway has been impli-
cated in various neurological processes like memory
formation and pain perception (reviewed in [16, 17]) but
also in the induction of cortical neurogenesis [18] and
development of the midbrain and cerebellum [19]. The
latter aspects are of particular relevance with respect to PA
pathogenesis, taking into account the high childhood
prevalence and cerebellar preponderance of these tumors,
and the accumulating evidence that neural stem/precursor
cells rather than post-mitotic glial cells constitute the origin
of glial neoplasms in general [20]. Indeed, there are several
reports in the literature indicating that PAs express a
number of markers, such as the PDGFa receptor, the NG2
proteoglycan, Sox10, and Olig2, similar to those of oligo-
dendrocyte precursor cells [21–29]. However, it is also
clear that the cellular effects of MAPK/ERK activation are
strongly context dependent. While several studies using
loss of function strategies of MEK and ERK have shown
that MAPK/ERK activation promotes a neuronal fate of
these early progenitors and represses glial differentiation
[18, 30], other groups report a role for ERK activation in
peri-lesional astrogliosis [31] and in oligodendrocyte dif-
ferentiation in the developing mouse cortex [32]. Further
work in this area is needed to investigate developmental
cell-type specific effects of MAPK activation, and a pos-
sible link to a cell of origin for PA. Besides these diverse
functions in the normal brain, altered MAPK/ERK signal-
ing has also been known for some time to play a major role
in the biology of higher grade astrocytomas (reviewed in
[33, 34]). The underlying aberrations, however, are dif-
ferent in most of these entities when compared with the
common mechanisms in pilocytic astrocytoma outlined
below. Rather than point mutations or gene fusions of RAF
family members, these tumors often harbor high-level
amplifications of upstream receptor tyrosine kinases such
as EGFR and PDGFR [35, 36] or somatic mutations of the
NF1 gene [36] as mechanisms for constitutive MAPK/ERK
activation.
Pilocytic astrocytoma and neurofibromatosis type 1
In contrast to the somatic mutations of NF1 seen in *15%
of glioblastomas [36, 37], the initial indication that MAPK
signaling might play a role in the development of PAs
came from clinical observations in patients with
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Neurofibromatosis Type 1 (NF1), which is caused by
germline NF1 mutation. Affecting around 1 in 4,000
individuals, it is one of the more common genetic disorders
and is inherited in an autosomal-dominant fashion with
almost 100% penetrance, although roughly 30–50% of
cases are due to new mutations [38, 39]. The product of the
NF1 gene is called neurofibromin, or NF1, and is a large
(220–250 kDa) protein that acts as a GTPase-activating
protein (GAP) for Ras. Loss of neurofibromin activity leads
to an increase in the active form of Ras, thereby contrib-
uting to tumor formation [40]. Neurofibromin has also been
implicated in maintaining progenitor cell pools in the CNS:
mutations in NF1 lead to an excessive accumulation of so-
called O-2A precursor cells (which can give rise to oligo-
dendrocytes or type-2 astrocytes in vitro depending on the
culture model) in transgenic mice, and also result in dis-
ruption of oligodendrocyte precursor cells in zebrafish [41–
43]. Furthermore, loss of NF1 can also lead to mTOR/AKT
pathway activation, which has been implicated in a more
aggressive subset of PAs [44]. The precise role of this
pathway in PAs, however, is yet to be fully determined.
NF1 is associated with an increased risk of glioma for-
mation, and PA is one of the most commonly involved
entities, accounting for about half of all NF1-associated
gliomas [45, 46]. Roughly 15% of NF1 patients have PAs,
particularly in the optic pathway [47], and optic pathway
gliomas are considered one of the diagnostic criteria for the
syndrome [48]. Conversely, about a third of tumors in the
optic pathway are PAs [49] and roughly 10% of all PAs are
NF1-associated, suggesting that PA patients, particularly
with optic pathway tumors, should be examined for clinical
signs of NF1 [50]. Mutation screening of NF1 can be dif-
ficult, since the gene comprises 58 exons spread over
nearly 300 kb of chromosome 17 and the types of muta-
tions observed can be complex. With the application of
high-throughput sequencing techniques, however, it will be
interesting to see whether either somatic NF1 mutations or
clinically undiagnosed germline NF1 alterations are also
seen in PAs.
One further important question that remains to be
answered, with respect to the role of NF1 in PA, is whether
it is possible to predict which patients with a clinical
diagnosis of neurofibromatosis type I will go on to develop
a pilocytic astrocytoma (or other glioma), and which of
those patients will suffer most from, for example, vision
loss or impairment. It was recently shown that there
appears to be some degree of genotype–phenotype corre-
lation in this syndrome, with NF1 patients harboring a
mutation in the first third of the gene more likely to
develop an optic pathway glioma [51]. Whether these
findings can be further expanded on, in order to clarify
a link between specific NF1 alterations and risk of
developing a PA, will be of particular interest both bio-
logically and from a clinical perspective.
In addition to NF1, pilocytic astrocytoma has also been
reported to occur in a small number of patients with
Noonan syndrome (NS) [52–54]. As with many of the
neuro-cardio-facial-cutaneous syndromes, NS is charac-
terized by germline alterations in MAPK pathway genes,
particularly PTPN11, SOS1, and KRAS (reviewed in [55]).
Whether this link is more than coincidental, and whether
PA is observed in any other hereditary MAPK pathway
disorders, are yet to be determined.
Gene fusions involving BRAF are a defining feature
of pilocytic astrocytoma
While a familial tumor syndrome first provided indirect
evidence for a link between MAPK signaling and PAs,
truly compelling evidence for the fundamental role of this
pathway in PA tumorigenesis came with the finding of a
highly frequent somatic rearrangement occurring in the
majority of sporadic cases. Focal duplication of approxi-
mately 2.5 Mb at 7q34 was reported as being a strikingly
common feature in pilocytic astrocytoma in 2008 [56–58],
although the exact significance of this alteration was not
immediately clear. Shortly thereafter, however, it was
shown that a gain in this region resulted in a novel fusion
between KIAA1549 (a large, as-yet uncharacterized gene)
and the BRAF oncogene [59, 60]. The study by Jones et al.
[59] further demonstrated that this fusion resulted in con-
stitutive activation of BRAF kinase activity, and was able
to transform NIH-3T3 cells. Since then, several additional
studies have reported similar findings, and contributed to
expanding our understanding of the frequency and speci-
ficity of this alteration [61–69]. The frequency of this
change stated in the literature varies from 50 to 100%
depending on the demographics of the patients investi-
gated, and a total of five different exonic combinations of
the two genes have been described (see Fig 1). The most
common (KIAA1549 exons 1–16 and BRAF exons 9–18,
or K:B16_9) comprises roughly 60% of fusion events, with
K:B15_9 accounting for *30% and K:B16_11 * 10%, with
minor contributions from rare variants. In all cases, how-
ever, the fusion leads to loss of the BRAF N-terminal auto-
regulatory domain and subsequent activation of the kinase
domain. This is in keeping with BRAF fusions previously
seen in a small fraction of thyroid tumors and large con-
genital melanocytic nevi, as well as rare RAF fusions
recently identified in melanoma, and in prostate and gastric
tumors [70–72]. Studies on larger numbers of PA cases are
now starting to identify links between clinical parameters
and BRAF fusion (as discussed below), but this is still an
MAPK signaling in pilocytic astrocytoma 1801
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area which will greatly benefit from further (prospective)
investigation in larger cohorts.
Apart from its high frequency, another striking feature
of the KIAA1549:BRAF fusion is its exquisite specificity to
PAs. Several reports looking at various additional low and
high malignancy grade pediatric brain tumors have found
no evidence for the fusion gene in these additional entities
[65, 67, 68, 73]. Whilst some studies have observed a small
number of cases of grade II astrocytoma, mixed oligo-
astrocytic tumors, or pilomyxoid astrocytomas harboring
the fusion gene, it is not currently clear whether these
might in fact represent misdiagnosed PAs with an unusual
histological composition [59, 60, 62, 64]. In the case of
pilomyxoid astrocytoma, in particular, it seems that this
may be part of a spectrum of PA morphology, perhaps
representing a slightly earlier, less-differentiated stage in
the tumor’s development, rather than an entirely distinct
entity. Indeed, there are reports of primary pilomyxoid
astrocytomas diagnosed early in life recurring later as
prototypic pilocytic tumors [74]. It is also not yet clear
whether the worse prognosis initially ascribed to these
tumors (warranting a malignancy grade II classification by
the WHO) is independent of the fact that they occur pre-
dominantly in surgically less-accessible regions and in
younger patients.
It is thus tempting to speculate that there may be
something unique to the PA cell of origin that allows this
fusion to drive oncogenesis solely in this tumor type.
Perhaps there is a ‘Goldilocks’ cell for this fusion, such that
the signaling induced is ‘just right’ to be tolerated and
induce transformation, where other cells may be insensitive
to the stimulus, die, or undergo immediate growth arrest.
The multiple, cell type-specific roles for MAPK signaling
in the brain, as discussed above, further support the
hypothesis that only a distinct cell type with certain
inherent properties and interactions with the microenvi-
ronment might be vulnerable to this mechanism of BRAF-
mediated transformation. An additional possibility is that
the transcriptional program of the PA precursor may lead to
a particular configuration of active and inactive chromatin
within the nucleus that brings the two genes in close
proximity and potentiates recombination. Elucidation of
the exact processes through which the 7q34 duplication
arises may help to shed light on the question of its speci-
ficity. Whilst the mechanism is still not entirely clear, a
recent study looking at the mapping of genomic break-
points suggested a possible recombination mechanism.
Lawson et al. [75, 76] identified an enrichment of sequence
microhomology, complex rearrangements, and proximity
to repeat elements, suggesting that the process of micro-
homology-mediated break-induced replication (MMBIR)
may be involved.
The presence of microhomology, ‘filler’ DNA and
sometimes complex rearrangements was also noted by Cin
et al. [61], who further reported a second mechanism of
BRAF fusion in a small number of PAs. In three cases
identified to date, a*2.5-Mb deletion at 7q34, telomeric to
BRAF, results in a fusion between it and the uncharacter-
ized gene FAM131B (Fig. 1). The resulting protein again
retained only the kinase domain of BRAF, and functional
analysis demonstrated constitutive kinase activity as well
as transformation of NIH-3T3 cells. Interestingly, the
breakpoints identified were close to the 50 end of FAM131B
and consisted primarily of 50 UTR. Only a short fragment
of the FAM131B protein is therefore included in these
fusions, suggesting that the 50 partner gene may be acting
primarily to induce transcription of the fusion and provide
a carrier for the BRAF kinase domain, rather than having a
functional protein role.
Alternative mechanisms of MAPK activation
The second most common change seen in PAs also
involves the BRAF gene, but consists of single amino acid
changes rather than gene rearrangement. Most often this is
the hotspot valine to glutamate change at position 600
(V600E), first identified in 2002 and since then reported in
a large number of tumor types ([77]; and see the Catalogue
of Somatic Mutations in Cancer (COSMIC) at http://www.
sanger.ac.uk/genetics/CGP/cosmic/ for further details). This
mutation has been extensively characterized and is a well-
documented oncogenic lesion [78, 79]. In addition, however,
a novel 3-bp (TAC) insertion encoding an extra threonine
Fig. 1 Schematic representation of the genomic and protein structure
of human BRAF and the fusion products detected in pilocytic
astrocytoma. The gene fusions with their indicated fusion partners and
break points in all cases result in a loss of the amino-terminal auto-
regulatory domain. This, as well as the V600E point mutation and the
Ins598T insertion in the full length protein, results in constitutive
activity of the kinase domain independent of upstream Ras status.
CR1-3 conserved region 1–3
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residue adjacent to the V600 hotspot codon has also been
reported in a few cases of PA [69, 80–82]. This alteration,
referred to as BRAFins598T or simply BRAFinsT, has been
shown to induce constitutive kinase activity at a level similar
to the V600E change, and it also shows transforming ability
in vitro [80, 81].
In stark contrast to the KIAA1549:BRAF fusion, the
V600E mutation does not appear to be specific to a brain
tumor entity. Two recent studies looking at BRAF muta-
tional status in a variety of entities, including a report
from the von Deimling group on more than 1,300 CNS
tumors, showed the presence of mutation in various sub-
types [73, 82]. Particularly high incidence was seen in
pleomorphic xanthoastrocytoma and ganglioglioma, sug-
gesting that BRAF activation has a broader role to play in
brain tumorigenesis, particularly in tumors of lower
malignancy grades. The elucidation of the exact down-
stream pathways involved is therefore a key target for
future research.
Another somatically mutated gene in PA, first reported
several years prior to the discovery of BRAFV600E, is
KRAS. In fact, one of the first identified somatic alterations
in pilocytic astrocytoma was a KRasQ61E mutation [83].
Further mutations in the hotspot codons 12, 13, and 61
have subsequently been found in several larger, indepen-
dent tumor series, but only at low frequency (\5%) [61, 62,
84, 85]. No mutations have yet been reported in HRAS or
NRAS in PA, suggesting that KRAS is likely the predomi-
nant isoform involved in the tumorigenic processes of PA.
Intriguingly, there is also evidence that tumor development
in an NF1 mouse model arises specifically from preferen-
tial activation of KRAS in astrocytes, further supporting
this hypothesis [86].
A further uncommon, yet still recurrent, mechanism of
MAPK pathway activation in pilocytic astrocytoma, so far
reported in only a few cases, is fusion of a second Raf
kinase family member, RAF1 (or CRAF) [61, 62, 81]. As
with the more frequent BRAF alteration, fusion between
RAF1 and SRGAP3 is also mediated by a tandem dupli-
cation event, occurring at 3p25. Several fusion junctions
have been reported, but all result in a truncated RAF1
kinase domain (Fig. 1). The fusion protein has also been
shown to possess constitutive kinase activity and trans-
forming ability [81]. Like the 7q34 duplication, this
alteration appears to be highly specific to PA, and it has so
far not been reported in any other tumor type.
Very few other genes have been reported to be mutated
in PAs, including those which are commonly associated
with higher grade astrocytomas. There are reports of
individual cases with mutations in TP53 and PTEN, for
example [87–90], and one report described a high fre-
quency of TP53 mutation. However, these findings have
not been replicated in more recent cohorts, and these genes
are currently not thought to play a major role in the
development of pilocytic astrocytoma.
The various alterations in the MAPK pathway described
here are usually seen to be mutually exclusive within PA,
suggesting that a single hit in the pathway may be sufficient
for transformation in most cases. However, rare co-occur-
rence of BRAFV600E with either KIAA1549:BRAF fusion or
clinically diagnosed NF1 has also been reported [61, 64,
80]. Indeed, one patient apparently carried all three of these
alterations [61]. The number of cases involved is currently
too small to assess whether patients with multiple hits in
the pathway generally show a worse clinical outcome.
Taken together, at least one hit in the MAPK pathway
has been identified in approximately 80–90% of PA cases
reported to date (see Fig. 2a). The question of which
alterations are responsible for the remaining cases remains
unclear, but is the subject of ongoing investigation in large-
scale genomics projects such as the International Cancer
Genome Consortium, and elsewhere [91]. These studies
should tell us in the foreseeable future whether this tumor
is truly associated solely with hits in the MAPK pathway,
or whether it also depends on as-yet unidentified secondary
alterations.
Clinicopathological correlates of MAPK alterations
With the growing number of reports on the incidence of
MAPK pathway alterations in PA, trends of association with
clinico-pathological parameters are starting to emerge. One
of the earliest recognized features, now confirmed in several
larger series, is an association between tumor location and
the types of MAPK aberration observed. Infratentorial
tumors (most commonly in the cerebellum) tend to show a
very high frequency of KIAA1549:BRAF fusion, while
supratentorial tumors generally show a lower proportion of
fusion-positive tumors, but an increased incidence of
BRAFV600E mutation [56, 61, 63–65, 82] (Fig. 2b). The
reason for this discrepancy, and its potential impact on tumor
behavior, is not currently clear, but the fact that a similar
propensity has been observed in multiple independent
studies suggests a genuine phenomenon. No histological
differences between BRAF fusion and mutant tumors have
been reported.
It has become apparent that there is a striking difference
in the proportion of BRAF fusion-positive cases between
pediatric and adult cases of PA, with the frequency getting
much lower with increasing age at diagnosis [63]. An
influence of age on genetic alterations has also been pre-
viously reported for larger-scale changes, with whole-
chromosome gains (particularly chromosomes 5 and 7)
being significantly more common in adult patients and
almost absent in the youngest patients [9]. The difference
MAPK signaling in pilocytic astrocytoma 1803
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in frequency of BRAF fusion is in contrast to the situation
in grade II astrocytomas, where signature changes that are
frequent in adult tumors (such as IDH1 and TP53 mutation)
are much less common in children [92]. This raises an
additional consideration in respect to the diagnostic utility
of BRAF fusion and IDH1 or TP53 mutation in different
age groups. The presence of a fusion in pediatric cases and
IDH1 or TP53 mutation in adult cases gives support for a
diagnosis of PA versus grade II astrocytoma, respectively.
It seems, however, that the absence of either change may
rather indicate a grade II astrocytoma in young patients but
pilocytic astrocytoma in adults. This feature, however, will
require careful assessment in larger, well-characterized
series.
An additional question, which will need addressing in a
larger series, is the impact of KIAA1549:BRAF and other
alterations on the prognosis of patients with PA. A study by
Hawkins and colleagues reported an association of BRAF
fusion with a favorable prognosis amongst 70 low-grade
astrocytomas (PAs and grade II diffuse/pilomyxoid astro-
cytomas), which they deemed ‘clinically relevant’; i.e.,
which were incompletely resected due to localization out-
side of the cerebellum [64]. In this subgroup, fusion-
positive tumors had a hazard ratio of 0.28 (95% CI,
0.14–0.58) for tumor progression compared with fusion-
negative counterparts. In contrast, looking solely at pilo-
cytic astrocytomas and in all tumor locations, Cin et al.
[61] did not find an association of KIAA1549:BRAF fusion
with progression-free survival. They did, however, report
both an age of B1 year and incomplete tumor resection as
independent factors of poor prognosis upon multivariate
analysis of 93 cases.
A B
Fig. 2 Distribution of oncogenic hits in the MAPK/ERK pathway by
tumor location. a Representation of the MAPK/ERK signal cascade.
Aberrations activating the pathway, i.e. activating mutations (star),
inactivating mutation of the repressor NF1 (X), fusions proteins and
unknown alterations (?), are indicated with their frequencies in
cerebellar and non-cerebellar PAs. Activation of this signaling
pathway can induce various cellular responses like cell growth,
differentiation, and oncogene-induced senescence (OIS). b The
various MAPK pathway alterations are unevenly distributed in
tumors of different locations. NF1 mutation is mainly seen in optic
pathway gliomas but also occasionally in other locations. Tumors in
other brain regions are dominated by RAF activation, with fusions
occurring primarily in cerebellar tumors and mutations in supraten-
torial PAs. For the more infrequent hits, no prevalent locations can be
given
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Oncogene-induced senescence in PA
In addition to clarifying the relationship between classes of
MAPK alteration and clinical/pathological factors, the next
advances in our understanding of PA biology will come
from determining the precise downstream consequences
of MAPK pathway activation in this tumor. Two recent
reports have taken steps addressing this issue, by demon-
strating that MAPK activation in PA leads to oncogene-
induced senescence (OIS) [93, 94]. OIS is a process of
growth arrest occurring as a tumor-suppressive mechanism
in response to oncogene activation [95]. Several links have
previously been made between the MAPK signaling path-
way and induction of OIS. Since being first described as a
response to oncogenic Ras signaling, senescence has now
also been shown to be induced by BRAF activation and
loss of NF1 activity [96, 97]. The papers on OIS in PAs by
Jacob et al. and Raabe and colleagues [93, 94] showed that
this phenomenon occurs both in vitro, in models of BRAF
activation in neural precursors, and also in cells from pri-
mary tumor samples (Fig. 3). The Jacob et al. study further
demonstrated a more generalized mRNA expression pat-
tern of OIS activation in two independent primary tumor
cohorts. It now seems likely that this process plays a major
role in restricting PA to its relatively slow growth pattern
and generally more benign behavior compared with higher
grade astrocytomas.
Interestingly, both these studies also pointed to a key role
of the p16 tumor suppressor in mediating the OIS process in
PAs, with the study of Raabe et al. reporting a link between
lack of p16 immunopositivity and worse clinical outcome.
This link fits with the observation of p16 loss in a subset of
PAs with histologically anaplastic features and poorer
prognosis [44]. Further investigation is needed to fully
assess the contribution of p16 immunostaining for prog-
nostication with respect to PA behavior. In addition, the
growth repression due to OIS in PAs appears to be less than
that in melanocytic nevi, which also frequently exhibit
BRAFV600E-dependent OIS and thereby an early growth
arrest [97], since PAs can often grow to quite a considerable
size before presenting as a symptomatic tumor. Hence, it
will be of great interest for the understanding of PA biology
to further investigate the mechanisms regulating the balance
between growth and senescence in the context of particular
mitogenic stimuli in the PA cell of origin. This may also
prove to have relevance for informing treatment decisions,
for example when to give adjuvant therapy versus a ‘watch
and wait’ approach.
Mouse models of MAPK-driven gliomagenesis
Activation of MAPK/ERK signaling in the murine brain
has repeatedly been used for the generation of experimental
gliomas. Various approaches initially utilized overexpres-
sion of oncogenic Ras, which alone or in combination with
PI3K pathway activation or loss of the tumor suppressors
Ink4a/Arf, p53 or PTEN, resulted in the development of
grade II–IV glioma [98–104]. The first model of PA
mimicked the optic pathway tumors resulting from germ-
line NF1 alteration. Constitutive homozygous deletion of
NF1 is embryonically lethal in mice [105], while hetero-
zygous animals do not develop astrocytic tumors [106].
The group of David Gutmann therefore applied an induc-
ible knockout approach to specifically delete the residual
copy of NF1 in astrocytes of otherwise NF1-heterozygous
mice (NF1flox/mut; GFAP-Cre), a situation corresponding to
that in NF1 patients [107]. These animals developed benign
lesions in the optic pathway with histologic similarity to
PA. Interestingly, homozygous deletion in astrocytes alone
was not sufficient for tumor induction in these studies,
suggesting that NF1 heterozygous cells in the microenvi-
ronment and other microenvironmental signals may
contribute to the development of these optic pathway gli-
omas (OPGs) [108, 109]. Two recent studies propose that
this effect is due to CXCL12 secretion from stromal cells
and infiltrating microglia, which show a growth promoting
effect on NF1-/- cells [110, 111]. In fact, conditional
deletion of NF1 in astrocytes, glial precursors and neurons
adjacent to the retina using GFAP-Cre has been shown to
induce OPGs, although with only a low penetrance [112].
Notably, loss of p53 either alone or with PTEN deletion in
addition to NF1 deficiency both result in the development
of glioblastoma [113, 114].
Fig. 3 Oncogene-induced senescence in pilocytic astrocytoma. Left
Excessive MAPK activation can induce irreversible cell cycle arrest
via the p16Ink4a/Rb or the p14Arf/p53 pathway. This state can be
determined, e.g., by the appearance of senescence-associated hetero-
chromatin foci (SAHF), immunostaining for p16Ink4a and p21Waf1 or
by the characteristic staining for senescence-associated-b-galactosi-
dase (SA-b-Gal) activity. Right Primary cultured pilocytic
astrocytoma cells display clear SA-b-Gal activity (image kindly
provided by Dr. Karine Jacob, McGill University Health Center
Research Institute)
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The first study to investigate the gliomagenic potential
of the RAF gene family was published by the group of Eric
Holland in 2008. They used the RCAS/Ntv-a somatic ret-
roviral gene transfer system to transduce nestin-positive
neural progenitor cells in vivo with an N-terminally
deleted, constitutively active variant of the human RAF1
gene. Expression of this RAF1 variant alone induced only
hyperplastic lesions, but in conjunction with Ink4a/Arf loss
or AKT overexpression it gave rise to high-grade gliomas
histologically similar to tumors induced with oncogenic
KRAS [115]. Robinson et al. used the same system for
expression of wild-type and V600E-mutant BRAF in vivo.
Again, BRAF expression resulted in the induction of
tumors only when combined with AKT activation or Ink4a/
Arf knockout [116]. The same group recently published
that MAPK/ERK pathway activation by the downstream
effector MEK instead of BRAF is also capable of driving
gliomagenesis in this setting, but the induced tumors were
again of higher grades [117].
We recently extended this analysis of BRAF in the
RCAS system with truncated versions of wild-type and
mutant BRAF corresponding to the portion retained in the
most frequent fusion genes [118]. While confirming pre-
vious results using the full length constructs, the truncated
form of mutated BRAF was sufficient to induce tumori-
genesis without any additional oncogenic hit. The
respective tumors resembled PA not only on histological
and immunohistochemical levels, with fibrous tissue tex-
ture, strong GFAP and phospho-Erk immunoreactivity as
well as a low proliferation index (Fig. 4a), but also with
respect to their benign behavior, since tumor-bearing ani-
mals do not typically succumb to the disease, even without
treatment (authors’ unpublished observations). In vitro, the
oncogenic BRAF variant induced MAPK signaling and
proliferation in primary astrocytes, both of which effects
could be abrogated by pharmacologic BRAF inhibition
[118] (Fig. 4b). These results confirmed that MAPK acti-
vation driven via BRAF is sufficient to induce PA in vivo
without requiring a cooperating second alteration. It will
now be of great interest to exploit this model system for
further investigation of PA tumor biology and for testing
novel targeted therapies in a pre-clinical setting, in order to
translate these advances into a benefit for PA patients.
Clinical challenges and future directions for treatment
of PAs
There are a number of clinical challenges with respect to the
management of patients with pilocytic astrocytoma. Surgi-
cal resection is the treatment of choice for pilocytic
astrocytoma in children, and, in comparison with higher-
grade gliomas and other malignant brain tumors, this
usually results in excellent long-term survival rates [7, 8,
119–121]. Because of the long-term survival of the
vast majority of patients, pilocytic astrocytoma is viewed as
a chronic disease by many pediatric neurooncologists.
Treatment approaches should therefore aim for efficacy not
only in terms of tumor growth control but also in terms of
managing tumor- and treatment-related acute and long-term
toxicity, and quality of life. For example, patients with
supratentorial midline tumors frequently present with visual
symptoms including nystagmus and loss of visual acuity. In
addition, disruption of the hypothalamic region can result in
endocrine problems such as growth failure, delayed onset of
puberty, or pituitary gland dysfunction. Infants with
supratentorial midline tumors may also suffer from dien-
cephalic syndrome, which is associated with failure to
thrive, weight loss, and cachexia. PAs located in the pos-
terior fossa cause headache, nausea, and vomiting due to
obstruction of the fourth ventricle and subsequent increased
intracranial pressure, as well as ataxia due to pressure on the
cerebellum. Tumors located in the cerebral hemispheres are
associated with epileptic seizures or hemiplegia, whilst
those arising in the brain stem can produce cranial nerve
palsies including oculomotor or facial nerve palsy, swal-
lowing difficulties, and tongue atrophy.
Although outcome after surgery is generally good,
complete surgical resection can only be achieved in around
half of all cases, when the tumor is located in surgically
accessible sites such as the posterior fossa. If the tumor
involves the optic pathway, or the hypothalamic or tha-
lamic regions, complete removal is impossible in a
majority of patients. In the case of tumor progression, non-
surgical treatment strategies including chemotherapy and
radiation therapy are usually implemented. Chemotherapy
protocols are frequently based on a carboplatinum/vin-
cristine regimen, and are most often applied to younger
children and patients with NF1 suffering from non-resect-
able progressive disease [120, 122, 123]. Older children
will typically receive local radiation therapy in the event of
tumor progression. These additional treatments increase the
risk of patients experiencing more severe side effects.
With the discovery of BRAF alterations and constitutive
activation of the downstream MAPK-pathway in the
majority of cases of pilocytic astrocytoma, targeted thera-
pies are now being recognized as potential novel treatment
approaches. There are currently a number of preliminary
phase I/II clinical trials ongoing which are testing small
molecule kinase inhibitors targeting the MAPK or related
pathways, including: MEK inhibitors (ClinicalTrials.gov:
NCT01386450, NCT01089101), RAF/multiple tyrosine
kinase inhibitors such as Sorafenib (ClinicalTrials.
gov: NCT01338857), and mTOR inhibitors in patients with
and without NF1 (ClinicalTrials.gov: NCT01158651,
NCT00782626). The outcome of these early clinical
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studies will be of great importance for the further devel-
opment of larger clinical trials for patients with pilocytic
astrocytoma in the forthcoming years.
Further advances in understanding the biology of pilo-
cytic astrocytoma, particularly in further elucidating the
precise roles and downstream effects of MAPK pathway
activation, also have the potential to greatly improve
diagnosis and prognostication of PAs, and also to offer
additional targets for novel therapeutic strategies. For
example, little is known about the underlying biological
factors determining the likelihood of progression of pilo-
cytic astrocytomas: whereas many of the patients with non-
completely resected tumors will exhibit early progression
within 1–2 years after surgery, about 20% will show long-
term stability over more than 10 years without any inter-
vention. In contrast to older children, small infants below
1 year of age have a poor prognosis and even succumb to
their disease in a large proportion of cases. Furthermore,
the biological factors determining spinal or leptomenigneal
dissemination are not known, nor are any predictors of
Fig. 4 BRAF-induced murine
pilocytic astrocytoma. a Tumors
induced by somatic gene
transfer of an activated form of
BRAF display histologic
features of human PA, including
fiber-rich tissue as well as a low
proliferation index (as assessed
by Ki67 immunopositivity),
clear GFAP immunopositivity,
and a strong activation of
MAPK signaling (illustrated by
ERK-phosphorylation; pErk).
b Expression of activated BRAF
induces proliferation in primary
murine astrocytes in vitro,
which can be markedly reduced
by treatment with the kinase
inhibitor Sorafenib
MAPK signaling in pilocytic astrocytoma 1807
123
response to chemotherapy or radiation treatment. All these
are areas which would benefit from additional research and
are currently under intensive investigation.
Summary
In conclusion, recent results in this field have proven highly
significant both in terms of dramatically increasing our
understanding of the basic biology behind pilocytic astro-
cytoma, and providing opportunities for rapid translation
into clinical benefit for patients. However, there remain a
number of pressing unanswered questions, including: What
are the precise downstream effects of MAPK signaling
activation in this tumor that lead to its behavior? Is PA a
single-pathway disease, and what occurs in the remaining
10–20% of PA cases without apparent MAPK signaling
alterations? How does cerebellar PA relate to supratentorial
PA or the pilomyxoid variant? And can we identify clini-
cally relevant subgroups (such as very young patients) with
inferior prognosis? We expect that currently ongoing
efforts, such as large-scale whole genome sequencing within
the International Cancer Genome Consortium (ICGC)
Pediatric Brain Tumor Project (http://www.pedbrain.org) as
well as many other studies worldwide, will be able to build
on the strong foundation provided in the last few years, and
drive continued progress towards combating the most
common pediatric brain tumor.
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